BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 16363700)

  • 1. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue.
    Uchino H; Niwa M; Shimizu T; Nishiyama K; Kawamori R
    Endocr J; 2000 Oct; 47(5):639-41. PubMed ID: 11200947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prandial glucose regulator and insulin secretagogue; glinide and its combination therapy].
    Nakashima E
    Nihon Rinsho; 2015 Mar; 73(3):416-23. PubMed ID: 25812367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of insulin secretion pattern lectured by "glinides" in the treatment of postprandial hyperglycemia].
    Hirose T
    Nihon Rinsho; 2005 Dec; 63(12):2237-44. PubMed ID: 16363700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Glinide(s), sulfonylurea(s)].
    Arakawa M; Hirose T
    Nihon Rinsho; 2006 Nov; 64(11):2107-12. PubMed ID: 17087304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nateglinide and mitiglinide].
    Odawara M
    Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of nateglinide in impaired glucose tolerance subjects].
    Hirose T
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
    Ikenoue T; Kondo N
    Nihon Yakurigaku Zasshi; 2000 Sep; 116(3):171-80. PubMed ID: 11031747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics of glinides.
    Chen M; Hu C; Jia W
    Pharmacogenomics; 2015 Jan; 16(1):45-60. PubMed ID: 25560470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.
    Pratley RE; Foley JE; Dunning BE
    Curr Pharm Des; 2001 Sep; 7(14):1375-97. PubMed ID: 11472274
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.